Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727094 | 1.00 | FABP5 (0.41) | FABP5FABP7CASP3KMT2AEPHX2 | |
| SCHEMBL31452146 | 0.89 | KMT2A (0.40) | FABP5FABP7CASP3KMT2AEPHX2 | |
| SCHEMBL725607 | 0.87 | FABP5 (0.40) | FABP5FABP7CASP3KMT2AEPHX2 | |
| SCHEMBL727087 | 0.87 | FABP5 (0.40) | FABP5FABP7CASP3KMT2AEPHX2 | |
| SCHEMBL25173108 | 0.85 | FABP5 (0.44) | FABP5FABP7CASP3KMT2AEPHX2 | |
| SCHEMBL8804802 | 0.85 | FABP5 (0.44) | FABP5FABP7CASP3KMT2AEPHX2 | |
| SCHEMBL29855110 | 0.85 | FABP5 (0.44) | FABP5FABP7CASP3KMT2AEPHX2 | |
| SCHEMBL30792881 | 0.84 | FABP5 (0.40) | FABP5FABP7CASP3KMT2AEPHX2 | |
| SCHEMBL27028773 | 0.84 | FABP5 (0.40) | FABP5FABP7CASP3KMT2AEPHX2 | |
| SCHEMBL27134348 | 0.84 | FABP5 (0.40) | FABP5FABP7CASP3KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2442829-B1 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3698811-A1 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3698810-A1 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10487129-B2 | Stabilized insulinotropic peptides and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-10273290-B2 | Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2590997-B1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180037636-A1 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-9822165-B2 | Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170260248-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9695224-B2 | Stabilized insulinotropic peptides and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160159876-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2016-06-09 | — | — | US | disclosed |
| EP-2590997-A2 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120141527-A1 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2442829-A2 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2012006598-A2 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2010148335-A2 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE | DANA FARBER CANCER INSTITUTE, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10487129-B2 | Stabilized insulinotropic peptides and methods of use | IAPP, VIP, GLP1R | FABP5 1594/4885FABP7 1665/4885CASP3 2601/4885 |
| US-20180037636-A1 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE | VIP, FURIN, HAVCR2 | FABP5 288/4885FABP7 750/4885CASP3 1197/4885 |
| US-20160159876-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | IAPP, VIP, GLP1R | FABP5 1594/4885FABP7 1665/4885CASP3 2601/4885 |
| US-10273290-B2 | Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides | NGLY1, HAVCR2, HM13 | FABP5 888/4885FABP7 1770/4885CASP3 982/4885 |
| US-20120141527-A1 | STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE | VIP, FURIN, HAVCR2 | FABP5 299/4885FABP7 756/4885CASP3 1187/4885 |
| US-20170260248-A1 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE | IAPP, VIP, GLP1R | FABP5 1594/4885FABP7 1665/4885CASP3 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.